Secondary root certificate maintains security of communications between servers and clients to facilitate a phased transition from current to quantum-safe cryptography

Printing Museum, Tokyo to present research findings on the Vatican Apostolic Library’s Greek Manuscripts at “How Masterpieces Are Born: Biblioteca Apostolica Vaticana Ⅲ+” Special Exhibition

Lixte Biotechnology (NASDAQ: LIXT) is emerging as a differentiated player in the oncology ecosystem, advancing a precision-driven approach to cancer treatment which focuses on improving the effectiveness of existing. As a clinical-stage pharmaceutical company, the company is advancing novel compounds built around a unique biological target, with its lead candidate, LB-100, at the nucleus of its […]

HONG KONG SAR - Media OutReach Newswire - 10 April 2026 - AilsynBio, an AI-driven drug discovery company, held an Innovative Project Cooperation Agreement Signing Ceremony today at the Hong Kong Science Park, announcing a project cooperation agreement with Dong-E-E-Jiao Co., Ltd. (000423.SZ). This partnership marks a profound cross-sector integration of Artificial Intelligence (AI) and traditional medicine, aiming to empower biopharmaceutical innovation through technological means. The ceremony brought together influential leaders and experts from industry, academia, and research sectors, including senior representatives from China Resources Pharmaceutical Group, Hong Kong Science and Technology Parks Corporation (HKSTP), and The University of Hong Kong (HKU), to witness this significant milestone. Dr. Bo Chen, Chief Scientific Officer of China Resources Pharmaceutical, noted: "This collaboration with Dong-E-E-Jiao and AilsynBio is a key initiative for China Resources Pharmaceutical in advancing the modernization of Traditional Chinese Medicine (TCM). It represents a deep integration of industry, academia, and research in the field of 'AI + TCM' between Mainland China and Hong Kong. We look forward to leveraging scientific research and industrial resources from both regions to overcome the challenges of TCM's mechanisms of action and to pave an innovative path for TCM to evolve from empirical medicine to evidence-based medicine." Mr. Liang Zheng, Vice President of Dong-E-E-Jiao, stated: "As a core strategic product for Dong-E-E-Jiao, deepening the scientific value of Compound E-Jiao Syrup is crucial for our brand upgrade. This cooperation will strengthen the scientific foundation of our products in the field of women's health, helping Dong-E-E-Jiao accelerate into a new stage of 'reshaping TCM wisdom through technological innovation.'" Mr. Pierre Wang, Managing Director of HKU Versitech Limited, stated: "HKU Versitech is honored to witness this project cooperation between HKU spin-off AilsynBio Ltd. and China Resources Pharmaceutical subsidiary Dong-E E-Jiao, a partnership that exemplifies the successful translation of Hong Kong's top-tier academic research into high-impact industrial applications. This cooperation will continue to serve as a vital catalyst for the company's rapid international growth and its mission to scale cutting-edge biotechnology globally." Looking ahead, the two parties will focus on three key collaborative directions: Advancing AI-driven innovation: Leveraging AilsynBio's AI drug discovery platform to accelerate biopharmaceutical R&D processes. Launching specialized research: Engaging in in-depth cooperation on the "Premature Ovarian Insufficiency (POI)" research project. Promoting cross-border fusion: Exploring the integration of biotechnology, AI, and traditional medicine to jointly create a new paradigm for the health industry. During the ceremony, AilsynBio and Dong-E-E-Jiao signed the agreement on behalf of their respective organizations. The signing was witnessed by Dr. Bo Chen, Chief Scientist of China Resources Pharmaceutical; Mr. Eric Or, Chief Ecosystem Development Officer of HKSTP; and Mr. Pierre Wang, Managing Director of HKU Versitech. AilsynBio stated that this cooperation is not only a combination of cutting-edge technology and traditional medicine, but also a strategic layout for future healthcare innovation. By leveraging AI technology, the partnership aims to inject technological vitality into traditional medicine for the benefit of more patients. Hashtag: #AilsynBio #昂心生物https://ailsynbio.com/The issuer is solely responsible for the content of this announcement.About China Resources PharmaceuticalChina Resources Pharmaceutical Group Limited (Stock code: 03320.HK) stands as a premier, integrated pharmaceutical enterprise in China. Our comprehensive operations span the entire value chain, from R&D and manufacturing to distribution and retail. We host a robust portfolio of listed subsidiaries and maintain advanced innovation platforms dedicated to both chemical and biological pharmaceuticals. Our diverse products including chemical drugs, Traditional Chinese Medicine (TCM), biologics, health supplements, and medical devices, addressing a vast spectrum of therapeutic areas. We are the proud custodian of iconic brands such as "999", "Dong-E-E-Jiao", and "Jiangzhong". Guided by our mission to "Safeguard Human Health and Enhance Quality of Life," we are dedicated to evolving into a trusted, innovation-driven leader in pharmaceutical and healthcare sector.About Dong-E E-JiaoDong-E E-Jiao Co., Ltd. (000423.SZ) is an enterprise engaged in the production and operation of E-Jiao and related products. As a subsidiary of state-owned China Resources Group, it is primarily involved in the R&D, production, and sales of E-Jiao and related Chinese patent medicines, health foods, and food products. The company, formerly known as Shandong Dong-E E-Jiao Factory, was established in 1952, listed on the Shenzhen Stock Exchange in 1996, and joined China Resources Group in 2005. The company houses the National Gelatin Traditional Chinese Medicine Engineering Technology Research Center and a postdoctoral research workstation. It is recognized as a National High-Tech Enterprise, a National Innovative Enterprise, a National Intangible Cultural Heritage Heritage Enterprise, and a National Traditional Chinese Medicine Culture Publicity and Education Base. Its products are sold not only in the domestic market but also in over 10 countries and regions, including Southeast Asia, Europe, and the Americas.About AilsynBioAilsynBio is an AI-native biotechnology company dedicated to the rational design of differentiated therapeutics. By combining artificial intelligence, physics-based modeling, and deep medicinal chemistry expertise, the company delivers end-to-end drug discovery solutions spanning novel target identification, mechanism-of-action elucidation, and lead design and optimization. Validated through collaborations with multiple top-tier pharmaceutical companies, AilsynBio's technology offers industry-leading predictive accuracy and enables the delivery of IND-ready candidate molecules with greater efficiency, higher success rates, and a fraction of the time and cost required by conventional approaches.

AI 赋能传统中药，共启大健康产业新篇章香港 - Media OutReach Newswire - 2026年4月10日 - AI药物研发公司 昂心生物 （AilsynBio） 今日于香港科学园举行项目合作签约仪式 ，宣布与 东阿阿胶股份有限公司（000423.SZ）达成项目合作协议 。此次合作标志着人工智能（AI）与传统医药的深度跨界融合，旨在透过科技赋能生物医药创新。 本次仪式汇聚了产、学、研各界的重量级嘉宾，包括华润医药集团、香港科技园公司及香港大学的高层领导与专家，共同见证这一重要里程碑 。 华润医药首席科学家陈波博士指出：此次与东阿阿胶及昂心生物的合作，是华润医药推动中医药现代化的一次重要实践，更是内地与香港在"AI+中药"领域产学研深度融合的探索。我们期待通过整合两地科研与产业资源，为破解中药作用机制难题、加速中医药从经验医学迈向循证医学提供创新路径。 东阿阿胶副总裁郑梁先生表示：复方阿胶浆作为东阿阿胶的核心战略大品种，其科学价值的深化对品牌升级至关重要。本次合作将为产品在女性健康领域的科学基础研究添砖加瓦，并成为传统中药与前沿科技跨界合作的标杆。 香港大学科桥有限公司董事总经理王光世先生表示，香港大学科桥有限公司 荣幸见证港大初创企业 昂心生物 与华润医药集团旗下 东阿阿胶 签约启动项目合作。此次合作充分体现了将香港顶尖学术研究成果转化为具备重大影响力之产业应用的成功范例。这项合作将助力其履行将前沿生物技术推向全球规模化应用的使命。 展望未来，双方将重点推进三大合作方向：一是推进 AI 驱动创新，利用 昂心生物 的 AI 药物发现平台以加速生物医药研发进程 ；二是开展专项研究，针对「卵巢早衰（POI）」研究项目进行深度合作 ；三是促进跨界融合，探讨生物技术、人工智能与传统中药之融合，携手开创大健康产业的新范式 。 在签约仪式上，昂心生物与东阿阿胶双方签署协议 。仪式由华润医药首席科学家陈波博士、香港科技园首席创科生态发展总监柯志成先生，以及香港大学科桥有限公司董事总经理王光世先生共同见证 。 昂心生物 表示，本次合作不仅是前沿技术与传统医药的结合，更是对未来医疗健康创新的战略布局 。透过 AI 技术的赋能，将为传统医药注入科技活力，造福更多患者 。 Hashtag: #AilsynBio #昂心生物https://ailsynbio.com/The issuer is solely responsible for the content of this announcement.关于华润医药华润医药集团有限公司（香港联合交易所股份代码：03320.HK）是中国领先的综合医药公司，主要从事医药研发、制造、分销及零售等业务，旗下拥有多家上市公司和化学药、生物药创新药研发平台。公司产品组合包括化学药品、中药、生物制剂、保健品及医疗器械等，覆盖广泛治疗领域，旗下拥有「999」「东阿阿胶」「江中」等多个知名品牌。公司秉承「守护人类健康 提升生命质量」的使命，致力于成为大众信赖、创新驱动发展的医药健康产业引领者。 关于东阿阿胶东阿阿胶股份有限公司（000423.SZ）是阿胶及系列产品生产经营企业，隶属央企华润集团，主要从事阿胶及系列中成药、保健食品和食品的研发、生产和销售。公司前身为山东东阿阿胶厂，1952年建厂，1996年在深交所挂牌上市，2005年加入华润集团。公司拥有国家胶类中药工程技术研究中心、博士后科研工作站，是国家高新技术企业、国家级创新型企业，同时也是国家级非物质文化遗产传承企业、全国中医药文化宣传教育基地。产品除国内市场外，还销往东南亚、欧美等10多个国家和地区。 关于昂心生物AilsynBioAilsynBio 是一家 AI-native 生物科技公司，致力于差异化治疗药物的理性设计。透过结合人工智能、基于物理的建模技术，以及深厚的药物化学专业知识，公司提供涵盖新靶点识别、作用机制解析，以及先导分子设计与优化的全流程药物研发解决方案。AilsynBio 的技术已在与多家全球顶尖制药公司的合作中获得验证，展现出业界领先的预测准确性，并能以更高效率、更高成功率，以及远低于传统方法的时间与成本，推进具 IND 申报潜力的候选分子交付。